Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

• To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients

Secondary objectives:

• To assess the forced titration on physician and patient satisfaction

• To evaluate the impact of training tools by means of patient profile

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• T2 insulin naïve patients

• Patients whom their physician is considering initiation of Lantus treatment

• Poor glycemic control 7,5 %10 %

• T2 treatment with OADs more than 3 months

• BMI<40 kg/m2

Exclusion Criteria:

• Impaired renal function (Cr>2mg/dl or current renal dialysis)

• Acute or chronic metabolic acidosis

• Active liver disease or serum ALT or AST >2,5 than normal

• History of hypoglycemia unawareness

• Diabetic retinopathy with surgery in the previous 3 months or planned within 3 months after study entry

• Pregnancy, breast feeding

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.